News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cianna Medical Announces Next Generation Technology SCOUT Radar Localization System To Provide Instant Response And Real-Time Distance Measurement



7/26/2017 10:19:43 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
- Clinical validation is underway and commercial availability for new system is expected in Q4 2017

ALISO VIEJO, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Cianna Medical, Inc. today announced that a next generation SCOUT® radar localization system is currently undergoing clinical validation and expects to announce its commercial availability in the fourth quarter of this year. This proprietary SCOUT technology will enable unprecedented instant response and real-time distance measurement for localizing non-palpable tumors during breast lesion excision surgery, making it the most advanced localizing system in the industry.

With SCOUT, a highly sophisticated reflector is precisely placed at the tumor site up to 30 days before a lumpectomy or surgical biopsy. During the procedure, the surgeon scans the breast using the SCOUT guide, which transmits 50 million pulses per second, to lock on to the reflector’s position. The console delivers instant response feedback when the guide comes in contact with the skin, providing both audible and visual indicators. The next generation SCOUT will measure and display distance in millimeters with ± 1mm accuracy, allowing surgeons to optimize their breast conservation strategies.

SCOUT, an FDA-cleared, non-radioactive, wire-free radar breast tumor localization system, is the world’s only technology that utilizes radar in human tissue. Previously published data establish SCOUT as an accurate and reliable method to localize and excise breast lesions. Since its market introduction in 2015, SCOUT has been adopted at over 150 leading medical facilities across the United States and it has been used in more than 15,000 patient procedures to date.

“The goal in breast conservation surgery is to preserve as much healthy breast tissue as possible while removing all detectable cancer cells. For women navigating the often difficult road of breast cancer treatment, every millimeter matters,” said Eduardo Chi Sing, Chief Technology Officer of Cianna Medical. “We are excited to provide this important advance in breast tumor localization. Based on performance testing to date, we believe that no other breast tumor localization technology currently on the market provides the level of accuracy attainable with the next generation SCOUT system.”

The operational efficiency of SCOUT has also been associated with potential cost savings. Data presented at the 2017 American Society of Breast Surgeons Annual Meeting[1] demonstrated a 29-minute difference in average operating room (OR) start delay times with SCOUT compared with traditional wire localization, a decrease of 72.5 percent (95% CI; p < .001). The study authors suggest that this reduction in OR waiting time could support a cost savings of nearly $2,000 per procedure.

“The innovation of next generation SCOUT technology demonstrates Cianna Medical’s ongoing commitment to improving the care and outcomes for women with breast cancer,” said Jill Anderson, President and CEO of Cianna Medical. “Our significant and sustained investment in research and development is a key innovation driver that will enhance our already robust growth and solidify our industry leadership.”

About SCOUT®
The FDA-cleared SCOUT system features a proprietary, highly sophisticated reflector that is precisely placed at the tumor site up to 30 days before a lumpectomy or surgical biopsy. During the procedure, the surgeon scans the breast using the SCOUT guide which emits 50 million pulses per second, allowing the surgeon to “lock” in on the reflector’s precise location with ± 1mm of accuracy. This higher level of localization precision allows better surgical planning that may improve cosmetic results, as less tissue may need to be removed. SCOUT has an exceptional detection range of 1mm – 60mm, documented migration of <1% across multiple studies, and is OR compatible.[2]

SCOUT has received significant recognition from medical societies and industry associations including, most recently, being honored as a Gold winner at the 2017 Medical Design Excellence Awards.

About Radar Technology
The SCOUT system uses highly sophisticated radar technology. Radar is used when unprecedented precision is required. Applications using radar include ground penetrating radar, automobile safety systems, flight control systems and antimissile and air-defense systems.

About Cianna Medical, Inc.
Cianna Medical is the world leader in wire-free breast localization and has been focused on breast conservation for over 10 years. Cianna Medical develops, manufactures and markets innovative medical technologies that reduce costs, improve quality and reduce the anxiety and stress breast cancer treatments place on women and their families. Cianna Medical’s world-class research, development and commercialization teams developed the world’s first non-radioactive, wire-free breast localization system and the world’s only technology that utilizes radar in tissue. Cianna Medical is focused on expanding applications that continually advance patient care. Its SCOUT and SAVI® Brachy technologies are FDA-cleared and address unmet needs in the delivery of radiation therapy, tumor localization and surgical guidance. Please visit www.ciannamedical.com for more information.

________________________________

[1] Hayes MK, Bloomquist EV, and Wright H. SAVI SCOUT® Improves Breast Surgery Operating Room Start Times Compared with Wire Localization. Presented at the American Society of Breast Surgeons 18th Annual Meeting. April 2017.
[2] Cox CE, Russell S, Prowler V, et al. A Prospective, Single Arm, Multi-site, Clinical Evaluation of a Nonradioactive Surgical Guidance Technology for the Location of Nonpalpable Breast Lesions during Excision. Ann Surg Oncol. 2016;23(10):3168-74.

Media Contact: Erich Sandoval LAZAR PARTNERS for Cianna Medical esandoval@lazarpartners.com (917) 497-2867

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES